GlassScriptPhysician profile
Russell Douglas Springer
NPI 1336123843
$5,482.89
in general payments reported to CMS, 2019-2025
24 companies · $915 in 2025
The $915 reported for 2025 was more than what 89% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $384 · 2020: $457 · 2021: $813 · 2022: $1,043 · 2023: $964 · 2024: $907 · 2025: $915.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,679 · Entertainment: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,678.80 |
| Entertainment | $108.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $1,699.77 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens, Misight Contact Lens |
| Alcon Vision LLC | $692.48 | 2019-2025 | Rocklatan, Eysuvis, Total30 |
| Sun Pharmaceutical Industries INC. | $689.97 | 2021-2025 | Cequa |
| Bausch & Lomb Americas INC. | $626.88 | 2022-2025 | Miebo, Infuse, Vyzulta |
| Oyster Point Pharma, INC. | $256.23 | 2022-2025 | Tyrvaya |
| Allergan, INC. | $253.95 | 2020-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $235.03 | 2019-2021 | |
| Abbvie INC. | $234.61 | 2022-2023 | Lumigan, Vuity |
| Novartis Pharmaceuticals Corporation | $156.11 | 2020-2022 | |
| Tarsus Pharmaceuticals, INC. | $147.09 | 2024-2025 | Xdemvy |
| Optos, INC. | $108.10 | 2023-2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Menicon America INC | $88.91 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $63.54 | 2020 | |
| Dompe US, INC. | $32.26 | 2025 | Oxervate |
| Abb Con-Cise Optical Group LLC | $31.94 | 2024 | Spectacle Lenses, Contact Lens |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $28.77 | 2024 | Vevye |
| Biotissue Holdings INC. | $25.53 | 2019-2025 | |
| Kala Pharmaceuticals, INC. | $23.51 | 2022 | |
| Carl Zeiss Meditec USA, INC. | $16.17 | 2025 | Cirrus Hd-Oct |
| Eyevance Pharmaceuticals LLC | $15.50 | 2019 | |
| Aerie Pharmaceuticals, INC. | $15.09 | 2021 | |
| Glaukos Corporation | $14.45 | 2020 | |
| Shire North American Group INC | $13.52 | 2019 | |
| Sight Sciences, INC. | $13.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Russell Springer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.